Accreditation/Credit Designation

U of Cinncinnati

The University of Cincinnati and Physicians Education Resources®, LLC (PER®), are both accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians and have collaborated to design and execute these live and enduring educational activities.

For accreditation purposes, the University of Cincinnati is responsible for certification and documentation of attendance for these activities.

The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this enduring material for a maximum 1.5 AMA PRA Category 1 Credits™.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca; Genomic Health, Inc.; Merck & Co., Inc. and Sanofi Genzyme.

Medical Crossfire®: Exploring the Latest Advancements in Prostate Cancer Care

Release Date: January 31, 2020
Expiration Date: January 31, 2021
Media: Internet - based

Activity Overview

In the past decade, the treatment armamentarium for advanced/metastatic, hormone-naïve, and castration-resistant prostate cancer (CRPC) has expanded dramatically, providing more choices and greater potential to improve clinical outcomes but also increasing the complexity of decision making in the clinic. The available agents have different mechanisms of action and different safety profiles and lead to different clinical outcomes. In this Medical Crossfire® activity, the expert panel will discuss the latest data regarding current and emerging therapeutic strategies for the management of prostate cancer across lines of care. A case-based, lively discussion will help place new developments into clinical context to help you optimize care for your patients with prostate cancer.

Benefits of Participating

  • Hear the latest updates on emerging strategies for the care of your patients with prostate cancer
  • Contextualize emerging data through challenging case-based scenarios across lines of care in prostate cancer
  • Benefit from discussion on how the experts best apply advances in the field of prostate cancer to manage the disease in their patients
  • Gain expert perspective on future directions in prostate cancer care

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca; Genomic Health, Inc.; Merck & Co., Inc. and Sanofi Genzyme.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review video files/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Videos” will be available for your reference.
  • In order to receive a CME Certificate, you must complete the activity.
  • Complete the Posttest and the Evaluation, and then click on “Request for Credit.” You may immediately download a CME Certificate upon completion of these steps.

Target Audience

This educational activity is directed toward oncologists and other healthcare professionals interested in the treatment of prostate cancer.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Describe emerging therapeutic options in prostate cancer across multiple patient populations and lines of care
  • Integrate novel clinical evidence into clinical practice to optimize the clinical outcomes of patients with prostate cancer
  • Optimize treatment sequences using novel agents for the treatment of patients with prostate cancer
  • Define strategies to proactively identify and mitigate adverse events associated with different prostate cancer treatment options

Faculty, Staff, and Planners’ Disclosures


Robert Dreicer
Robert Dreicer, MD, MS, MACP, FASCO
University of Virginia Cancer Center
University of Virginia
Charlottesville, VA

Disclosures: Consultant: Seattle Genetics, Astellas, Pfizer, Novartis, Vizuri, Orion, Genentech

William K. Oh
William K. Oh, MD
Chief, Division of Hematology and Medical Oncology
Deputy Director, Tisch Cancer Institute
Professor of Medicine and Urology
Ezra M. Greenspan, MD Professor in Clinical Cancer Therapeutics
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosures: Consultant: Astellas, AstraZeneca, Bayer, Janssen, Sanofi, Sema4, TeneoBio

Elizabeth Plimack
Elizabeth Plimack, MD, MS
Chief, Division of Genitourinary Medical Oncology
Director, Genitourinary Clinical Research
Professor, Department of Hematology/Oncology
Fox Chase Cancer Center
Philadelphia, PA

Disclosures: Grant Research Support: Astellas, BMS, Genentech, Merck; Consultant: BMS, Flatiron, Genentech, Janssen, Merck, Seattle Genetics, AstraZeneca, Pfizer; Other: CME honoraria recipient: AUA, Clinical Care Options, Fox Chase Cancer Center, Georgetown, Medscape, NCCN, PER, PriME Oncology, Research to Practice

Susan F. Slovin
Susan F. Slovin, MD, PhD
Attending Physician, Member
Genitourinary Oncology Service
Sidney Kimmel Center for Prostate and Urologic Cancers
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill-Cornell Medical College
New York, NY

Disclosures: no relevant financial relationships with commercial interests to disclose.

Scott T. Tagawa
Scott T. Tagawa, MD, MS, FACP
Richard A. Stratton Associate Professor in Hematology and Oncology
Medical Director, Genitourinary Oncology Research Program
Associate Professor of Clinical Medicine and Urology
Weill Cornell Medicine
New York, NY

Disclosures: Grant Research Support: Research support (to Weill Cornell Medicine): Sanofi, Medivation, Astellas, Janssen, Amgen, Progenics, Dendreon, Lilly, Genentech, Newlink, BMS, Inovio, AstraZeneca, Immunomedics, Novartis, Aveo, Rexahn, Atlab, Boehringer Ingelheim, Millennium, Bayer, Merck, AbbVie, Karyopharm, Endocyte, Clovis, Seattle Genetics; Consultant: Sanofi, Medivation/Astellas, Dendreon, Janssen, Genentech, Bayer, Endocyte, Eisai, Immunomedics, Karyopharm, AbbVie, Tolmar, Seattle Genetics, Amgen, Clovis, QED, Pfizer

The staff of the University of Cincinnati and Physicians’ Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of the University of Cincinnati and PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, the University of Cincinnati PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, the University of Cincinnati and PER® are required by ACCME to resolve all COI. The University of Cincinnati and PER® have identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of the University of Cincinnati or PER® or the company that provided commercial support.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By